BACKGROUND: Adverse effects from childhood leukemia treatment may persist or present years after cure from cancer. We provide a comprehensive evaluation of subsequent hospitalization in five-year survivors of childhood acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). METHODS: In the Adult Life after Childhood Cancer in Scandinavia Study, we identified 4003 five-year survivors diagnosed with childhood leukemia 1970-2008 in Denmark, Sweden, Iceland, and Finland. Survivors and 129 828 population comparisons were followed for first-time nonpsychiatric hospitalizations for 120 disease categories in the hospital registries. Standardized hospitalization rate ratios and absolute excess rates were calculated. All statistical tests were two-sided. RESULTS: Survivors of ALL (n = 3391), AML (n = 389), and CML (n = 92) had an increased overall hospitalization rate compared with population comparisons. The rate ratio for any hospitalization was 1.95 (95% confidence interval [CI] = 1.83 to 2.07) in ALL, 3.09 (95% CI = 2.53 to 3.65) in AML, and 4.51 (95% CI = 3.03 to 6.00) in CML survivors and remained increased even 20 years from leukemia diagnosis. Corresponding absolute excess rates per 1000 person-years were 28.48 (95% CI = 24.96 to 32.00), 62.75 (95% CI = 46.00 to 79.50), and 105.31 (95% CI = 60.90 to 149.72). CONCLUSION: Leukemia survivors have an increased rate of hospitalization for medical conditions. We provide novel insight into the relative and absolute rate of hospitalization for 120 disease categories in survivors of ALL, AML, and CML, which are likely to be informative for both survivors and healthcare providers.
BACKGROUND: Adverse effects from childhood leukemia treatment may persist or present years after cure from cancer. We provide a comprehensive evaluation of subsequent hospitalization in five-year survivors of childhood acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). METHODS: In the Adult Life after Childhood Cancer in Scandinavia Study, we identified 4003 five-year survivors diagnosed with childhood leukemia 1970-2008 in Denmark, Sweden, Iceland, and Finland. Survivors and 129 828 population comparisons were followed for first-time nonpsychiatric hospitalizations for 120 disease categories in the hospital registries. Standardized hospitalization rate ratios and absolute excess rates were calculated. All statistical tests were two-sided. RESULTS: Survivors of ALL (n = 3391), AML (n = 389), and CML (n = 92) had an increased overall hospitalization rate compared with population comparisons. The rate ratio for any hospitalization was 1.95 (95% confidence interval [CI] = 1.83 to 2.07) in ALL, 3.09 (95% CI = 2.53 to 3.65) in AML, and 4.51 (95% CI = 3.03 to 6.00) in CML survivors and remained increased even 20 years from leukemia diagnosis. Corresponding absolute excess rates per 1000 person-years were 28.48 (95% CI = 24.96 to 32.00), 62.75 (95% CI = 46.00 to 79.50), and 105.31 (95% CI = 60.90 to 149.72). CONCLUSION:Leukemia survivors have an increased rate of hospitalization for medical conditions. We provide novel insight into the relative and absolute rate of hospitalization for 120 disease categories in survivors of ALL, AML, and CML, which are likely to be informative for both survivors and healthcare providers.
Authors: Lisa Diller; Eric J Chow; James G Gurney; Melissa M Hudson; Nina S Kadin-Lottick; Toana I Kawashima; Wendy M Leisenring; Lillian R Meacham; Ann C Mertens; Daniel A Mulrooney; Kevin C Oeffinger; Roger J Packer; Leslie L Robison; Charles A Sklar Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Ulla M Saarinen-Pihkala; Carsten Heilmann; Jacek Winiarski; Anders Glomstein; Jonas Abrahamsson; Johan Arvidson; Albert N Békássy; Erik Forestier; Gudmundur Jonmundsson; Henrik Schroeder; Kim Vettenranta; Finn Wesenberg; Göran Gustafsson Journal: J Clin Oncol Date: 2006-12-20 Impact factor: 44.544
Authors: G Socié; R A Clift; D Blaise; A Devergie; O Ringden; P J Martin; M Remberger; H J Deeg; T Ruutu; M Michallet; K M Sullivan; S Chevret Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: K Scott Baker; James G Gurney; Kirsten K Ness; Ravi Bhatia; Stephen J Forman; Liton Francisco; Philip B McGlave; Leslie L Robison; David S Snyder; Daniel J Weisdorf; Smita Bhatia Journal: Blood Date: 2004-06-01 Impact factor: 22.113
Authors: Daniel A Mulrooney; Douglas C Dover; Suwen Li; Yutaka Yasui; Kirsten K Ness; Ann C Mertens; Joseph P Neglia; Charles A Sklar; Leslie L Robison; Stella M Davies Journal: Cancer Date: 2008-05-01 Impact factor: 6.860
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Rajen Mody; Suwen Li; Douglas C Dover; Stephen Sallan; Wendy Leisenring; Kevin C Oeffinger; Yutaka Yasui; Leslie L Robison; Joseph P Neglia Journal: Blood Date: 2008-03-11 Impact factor: 25.476
Authors: Eleanor Kane; Sally Kinsey; Audrey Bonaventure; Tom Johnston; Jill Simpson; Debra Howell; Alexandra Smith; Eve Roman Journal: BMJ Open Date: 2022-03-07 Impact factor: 2.692
Authors: Marianne Agerlund Petersen; Carina Agerbo Rosenberg; Marie Bill; Marie Beck Enemark; Ole Rahbek; Anne Stidsholt Roug; Henrik Hasle; Bent Honoré; Maja Ludvigsen Journal: Cancers (Basel) Date: 2022-07-22 Impact factor: 6.575